传统大药企的创新狂潮,真的是杀疯了。从恒瑞医药成功赴港上市、创新药收入占比突破50%,到三生制药与辉瑞达成超60亿美元BD合作震动业界,再到石药集团与阿斯利康达成超53亿美元合作,无不彰显传统Pharma龙头的创新崛起。另一边,中国生物制药也不甘落后:一则,凭借12项临床研究入选2025 ASCO年会口头报告,创下中国药企的新纪录;二则,在近期举办的第46届高盛全球医疗健康年会上,资本市场负责人...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.